VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
16 juin 2019 12h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Cytovance® Biologics Inc., Completes Its Second FDA Pre-Approval Inspection (PAI) of Oklahoma City, OK Facilities
14 juin 2019 12h15 HE
|
Cytovance Biologics
OKLAHOMA CITY, June 14, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics announced that it has received a notification letter and an Establishment Inspection Reports (EIRs) from the U.S. Food and Drug...
NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
12 juin 2019 08h00 HE
|
IHMA Inc
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl...
SERSTECH AB: Serstech significantly expands its R&D capacity
11 juin 2019 06h00 HE
|
SERSTECH AB
Serstech is expanding its R&D team and today added its fifth new team member since early May. With the additional engineers in place, Serstech has more than doubled its R&D capacity in...
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy
05 juin 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 05, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
Elixinol Issues a Statement Following the Public FDA Hearing in Washington, D.C. on Friday, May 31
03 juin 2019 11h06 HE
|
Elixinol LLC
DENVER, June 03, 2019 (GLOBE NEWSWIRE) -- Elixinol issued the following statement regarding the public FDA hearing in Washington, D.C. on Friday, May 31. “We support the FDA’s intentions, we want...
Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer
29 mai 2019 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced...
Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
28 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
Emerald Health Therapeutics to Lead International Affairs Council on CBD and Hemp’s Dialog with FDA on CBD Product Policy as Part of the American Trade Association for Cannabis and Hemp
24 mai 2019 08h00 HE
|
Emerald Health Therapeutics Inc.
VANCOUVER, British Columbia, May 24, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has been appointed by the American Trade Association for...
BioElectronics Announces Withdrawal and Planned Resubmission of 510(k) for General Musculoskeletal Pain
22 mai 2019 10h43 HE
|
BioElectronics Corporation
FREDERICK, MD, May 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, announced today...